<DOC>
	<DOCNO>NCT00845000</DOCNO>
	<brief_summary>This randomize , placebo-controlled , 3-period crossover , balance , single-site , third party-blind study preladenant ( SCH 420814 ) participant Parkinson disease ( PD ) conduct conformance Good Clinical Practices . This trial investigate effect single dos preladenant placebo dyskinesia antiparkinsonian action levodopa infusion . The study examine 10 mg ( `` low dose '' ) 100 mg ( `` high dose '' ) study drug , give single , oral administration conjunction intravenous ( IV ) levodopa infusion oral carbidopa .</brief_summary>
	<brief_title>Acute Effects Preladenant ( SCH 420814 ) Dyskinesia Parkinsonism Levodopa Treated Participants ( P05550 )</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Parkinsonian Disorders</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Participant must diagnosis idiopathic PD base history , exam relevant laboratory test Participants must treat levodopa one year Participants must motor fluctuation measure 10 % change tap speed `` '' `` '' concurrent motor Unified PD Rating Scale ( UPDRS ) must also show 20 % improvement `` '' Participants must dyskinesia `` '' measure least 2 one body part scale use 0 ( absent ) 4 ( severe ) four limb , trunk , neck face ( total 7 body part 28 point ) Participant must free clinically significant disease would interfere study evaluation Female participant must postmenopausal and/or surgically sterilize negative serum pregnancy test screen visit negative urine serum pregnancy test upon admission study center Premenopausal , unsterilized female participant agree use medically accept method contraception Male participant must agree use medically accept method contraception abstain sexual intercourse trial 2 month stop medication . Female participant pregnant , intend become pregnant ( within 3 month end study ) , lactate Participants dementia ( minimental state examination [ MMSE ] &lt; 23 ) , hallucination , confusion , major psychiatric disorder , unstable medical condition Participants stable surgical medical condition might significantly alter absorption , distribution , metabolism excretion drug Participants positive screen drug abuse Participants positive hepatitis B surface antigen , hepatitis C antibodies human immunodeficiency virus ( HIV ) Participants currently participate another medical interventional clinical study participate medical interventional clinical study within 30 day previously receive compound .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>